COMPOUND | MOLECULAR TARGET | PATHWAY | CONDITIONS | Ref |
PR73 (only preclinical models) PTG300 (Rusfertide) LJPC-401 | FPN | Hepcidin mimetics, ferroportin inhibitors | B-THALASSEMIA, HAEMOCHROMATOSIS | [93] [94] [95] |
Anticalins PRS-080 | Hepcidin | Hepcidin antagonist, ferroportin stimulation | HEALTHY VOLUNTEERS, CHRONIC KIDNEY DISEASE | [96] |
Sodium-glucose cotransporter 2 inhibitors | Hepcidin, Erythropoietin | Reduction hepcidin pathway ferroportin stimulation | ANEMIA, IRIDA , HF | [97] [98] [99] |
Tmprss6 | Anti Matriptase-2 (antibody) | Increased emojuvelin pathway Increased hepcidin pathway | DISORDERS OF EYTHROPOIESIS AND IRON HOMEOSTASIS (IRON OVERLOAD AND DEFECTS) | [100] [101] |
H5F9-AM8 (preclinical models) | Emojuvelin (antibody) | Reduced emojuvelin Pathway Reduction hepcidin pathway | IRON IN MOUSE LIVER AND TUMOR XENOGRAFTS | [102] |
Anti BMP, Anti cytokines Interleukin (IL)-6 IL-1β, anti TGF 23 | Cytokines | STAT 3- and SMAD/ hepcidin pathway inhibitors | ANEMIA OF INFLAMMATION | [103] [104] [105] |
Vamifeport (VIT-2763) | FPN | ferroportin inibition | HEALTHY VOLUNTEERS | [106] [107] |
GDF 15 | Cytokines (IL6-1) | Reduction BMP/hepcidin pathway | IDA | [108] |
SPIRONOLACTONE | Hepcidin | Suppression hepcidin expression | IDA | [109] |
IMATINIB | Hepcidin | Suppression hepcidin expression | IDA | [109] |
HEPARIN | Hepcidin/BMP | hepcidin antagonist | IDA | [110] |
ERYTROFERRONE | BMP6 inibition | Reduction hepcidin pathway | IDA | [111] |